

PROGRAMME OF LIVE SESSIONS: CEST timing

The programme below will take place live. This time schedule corresponds to CEST timing. [Click here \(https://www.calculator.net/time-zone-calculator.html\)](https://www.calculator.net/time-zone-calculator.html) to adapt the CEST time schedule to your own time zone.

If you want to ask questions during the Panel Discussions, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting!



**9th Translational Research E-Conference
MYELOPROLIFERATIVE NEOPLASMS
May 12-15, 2022
#ESHMPN2022**

Chairs: Jean-Jacques Kiladjian, Ross L. Levine, Alessandro M. Vannucchi

Thursday, May 12, 2022

14:00-14:05 Welcome: Jean-Jacques Kiladjian, Ross L. Levine, Alessandro M. Vannucchi

SESSION I – Molecular pathogenesis of MPNs

Chair: Raajit K. Rampal (New York)

14:05-14:10 Introduction

14:10-14:30 Lessons about MPN pathogenesis from germline and somatic studies Radek Skoda (Basel)

14:30-14:50 MPN stem/cell directed therapeutics Ronald Hoffman (New York)

14:50-15:10 Molecular pathogenesis of progression from MPN to AML Raajit K. Rampal (New York)

15:10-15:20 Brief oral communication
Loss of Dnmt3a confers resistance to Pegifna in JAK2-V617F positive MPN Jan Stetka (Basel)

15:20-15:50 Panel discussion

15:50-16:00 Coffee Break

SESSION II – Novel MPN therapeutics

Chair: Radek Skoda (Basel)

- 16:00-16:05 Introduction
- 16:05-16:25 Targeting the MAPK pathway to enhance disease modification in MPN Sara Meyer (Bern)
- 16:25 -16:45 Structure based insights into MPN therapeutics Stefan N. Constantinescu (Brussels)
- 16:45-16:55 Brief oral communication
Inhibition of Interleukin-1 β reduces the evolution of myelofibrosis and osteosclerosis in a preclinical mouse model of JAK2-V617F driven MPN Shivam Rai (Basel)
- 16:55-17:25 *Panel discussion*
- 17:35-18:35 Mentored Poster Walk**
Leaders: David Kent (York), Sara Meyer (Bern)

Friday, May 13, 2022

13:00-14:00 SATELLITE SYMPOSIUM

Controversies in Myelofibrosis: Defining and Measuring Disease Modification

Chair: Naveen Pemmaraju (Houston)

Speakers: Naveen Pemmaraju (Houston), Francesco Passamonti (Varese)

This symposium is organized and sponsored by AbbVie

SESSION III – MPN Initiation and clonal evolution

Chair: Simón Méndez-Ferrer (Cambridge)

- 14:10-14:15 Introduction
- 14:15-14:35 Single cell studies to uncover novel insights into MPN pathogenesis Adam Mead (Oxford)
- 14:35-14:55 Role of inflammation in MPN initiation and progression Angela Fleischman (Irvine)
- 14:55-15:15 Non-genetic mechanisms of clonal expansion David Kent (York)
- 15:15-15:25 Brief oral communication
HMGA1 chromatin regulators induce transcriptional networks involved in cell fate and proliferation during MPN progression Linda Resar (Baltimore)
- 15:25-15:55 *Panel discussion*
- 15:55-16:05 Coffee break**

SESSION IV – Murine MPN models and pathogenesis/therapeutic studies

Chair: Ann Mullally (Boston)

16:05-16:10	Introduction	
16:10-16:30	Targeting the microenvironment as a therapeutic approach in MPN	Simón Méndez-Ferrer (Cambridge)
16:30-16:50	NGS analysis and evaluation of clonal evolution during treatment in MPN in clinical practice	Bruno Cassinat (Paris)
16:50-17:10	Pathogenesis and therapy of MPN-associated thrombosis	Chloé James (Bordeaux)
17:10-17:35	Keynote lecture: New Insights into the role of JAK2V617F in MPN pathogenesis	Ross L. Levine (New York)
17:35-17:45	<u>Brief oral communication</u> <i>Different niches for ET and PV HSCs affect disease development and response to therapy</i>	Elodie Grockowiak (Cambridge)
17:45-18:05	<i>Panel discussion</i>	

18:15-19:15 SATELLITE SYMPOSIUM

Bridging the Gap: Novel combination approaches in MPN

Chair: Claire Harrison (London)

Speakers: Francesca Palandri (Bologna), Adam Mead (Oxford)

This symposium is organized and sponsored by MorphoSys/Constellation

19:25-20:25 3 Simultaneous Meet the Experts sessions (non-clinical):

- | | |
|--|--------------------------------------|
| 1. Role of inflammation in MPN | Angela Fleischman (Irvine) |
| 2. Cellular and molecular regulators of HSCs in myeloid malignancies | David Kent (York), Sara Meyer (Bern) |
| 3. HSC niches in MPN | Simón Méndez-Ferrer (Cambridge) |

Saturday, May 14, 2022

13:00-14:00 SATELLITE SYMPOSIUM

Future directions: Defining disease modification and its relevance in clinical practice

Chair: Jean-Jacques Kiladjian (Paris)

Speakers: Srdan Verstovsek (Houston), Florian Heidel (Greifswald)

This symposium is organized and sponsored by Bristol Myers Squibb

SESSION V – Molecular pathogenesis and therapy of MPN progression and leukaemic transformation

Chair: Raajit K. Rampal (New York)

14:10-14:15 Introduction

14:15-14:35 Unusual forms of eosinophilias
(FGFR1 inhibitors, MoAb for other eosinophilias) Andreas Reiter (Mannheim)

14:35-14:55 Therapeutic approaches in post-MPN AML John O. Mascarenhas (New York)

14:55-15:15 Transplantation as therapeutic in MPN in accelerated phase or transformed AML Nicolaus Kröger (Hamburg)

15:15-15:25 Brief oral communication
Influence of clonal architecture on clinical course in patients with myeloproliferative neoplasms Damien Luque Paz (Basel)

15:25-15:55 *Panel discussion*

15:55-16:05 Coffee break

SESSION VI – Recent advances in therapeutics (1)

Chair: Jean-Jacques Kiladjian (Paris)

16:05-16:10 Introduction

16:10-16:35 **Keynote lecture:** Combination therapies for myelofibrosis Ruben Mesa (San Antonio)

16:35-16:55 Prognostic scores in MPN Alessandro M. Vannucchi (Florence)

16:55-17:05 Brief oral communication
Engineered calreticulin mutant human hematopoietic stem and progenitor cells recapitulate myeloproliferative phenotypes and reveal novel mutation-specific vulnerabilities Johannes Fosselteder (Graz)

17:05-17:35 *Panel discussion*

17:35-18:05 Coffee break

SESSION VII – Recent advances in therapeutics (2)

Chair: Alessandro M. Vannucchi (Florence)

18:05-18:10 Introduction

18:10-18:30 Insights in diagnosis and management of CMML Eric Solary (Paris)

18:30-18:50 Why Hydroxyurea must still be the standard in patients with Essential Thrombocythemia Tiziano Barbui (Bergamo)

18:50-19:10 Therapy of overlap MPN/MDS syndromes Lionel Adès (Paris)

- 19:10-19:20 Brief oral communication
Expression of CD47 and Calr in myeloproliferative neoplasms: potential new therapeutical targets *Ciro Rinaldi (Lincoln)*
- 19:20-19:50 *Panel discussion*

Sunday, May 15, 2022

13:00-14:00 3 Simultaneous Meet the Experts Sessions (Clinical):

1. Novel and Emerging Therapeutic Approaches for MPNs Raajit K. Rampal (New York), Ross L. Levine (New York)
2. How to recognize and manage ruxolitinib treatment failure? John O. Mascarenhas (New York),
Alessandro M. Vannucchi (Florence)
3. MPN diagnosis: the place of red cell mass measurement in the molecular era Stéphane Giraudier (Paris), Jean-Jacques Kiladjian (Paris)

SESSION VIII – Molecular pathogenesis of MPNs

Chair: Angela Fleischman (Irvine)

- 14:10-14:15 Introduction
- 14:15-14:35 CALR mutations in the development of MPN using mouse modeling Caroline Marty (Villejuif)
- 14:35-14:55 Novel genetic and therapeutic vulnerabilities in CALR-mutant MPN Ann Mullally (Boston)
- 14:55-15:15 Deciphering the role of clonal evolution in MPN pathogenesis and progression Andrew Dunbar (New York)
- 15:15 -15:25 Brief oral communication
Srsf2P95H prevents Jak2V617F-induced myelofibrosis and hematopoietic stem cell exhaustion *Christophe Willekens (Villejuif)*
- 15:25-15:55 *Panel discussion*

15:55-16:05 Coffee break

SESSION IX – Novel MPN therapeutics

Chair: Stefan N. Constantinescu (Brussels)

- 16:05-16:10 Introduction
- 16:10-16:30 Targeting splicing factors Timothy Graubert (Boston)
- 16:30-16:50 Targeting aberrant self-renewal in MPN Catriona Jamieson (La Jolla)
- 16:50-17:10 Novel approaches to mastocytosis therapy Jason Gotlib (Stanford)

17:10-17:20 Brief oral communication

*Rusfertide (PTG-300) treatment effectively controls
hematocrit to eliminate need for therapeutic
phlebotomy in polycythemia vera patients*

Marina Kremyanskaya (New York)

17:20-17:50 *Panel discussion*

17:50-18:00 Closing Remarks

MEETING CLOSURE